Low molecular weight proteins and the kidney: physiologic and pathologic considerations

Comparison of Urinary Beta-2 Microglobulin Levels in Children with SSNS and Calcineurin Inhibitor-Treated SRNS

Background

While the utility of beta-2 microglobulin (β2M) has been explored in various renal conditions to identify tubulointerstitial damage, it has not been adequately studied in nephrotic syndrome. The primary objective of the study was to compare urinary β2M levels in children with steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) in disease remission.

Materials and Methods

This cross-sectional study was done at a tertiary care hospital between April 2019 and March 2020. Sixty children (2-18 years) with SSNS and SRNS (30 in each group) in remission were enrolled. SRNS patients were included after ≥1 year of treatment with calcineurin inhibitors (CNIs). Biochemical investigations were done to confirm remission; spot samples for urinary β2M were collected and estimation was done by an enzyme-linked immunosorbent assay (ELISA)-based kit.

Results

Of the 60 children, 63% were boys. The median (interquartile range [IQR]) age at enrollment for SSNS and SRNS patients was 7 (4.1-9) and 11 (8.3-12) years, respectively. Urinary β2M levels were significantly higher in SRNS patients compared to SSNS patients (2.6 vs. 0.75 mg/ml, P < 0.0001). Patients who received cyclosporine for >2 years had higher median urinary β2M levels compared to those who received it for a shorter period (2.63 vs. 1.83 mg/ml, P = 0.03). Median β2M levels were higher in focal segmental glomerulosclerosis than minimal change disease (3.5 vs. 2.5 mg/ml).

Conclusion

Urinary β2M levels were higher in SRNS compared to SSNS disease in remission, and β2M levels correlated well with CNI use of >2 years. It appears to be a promising noninvasive tool to identify early tubular damage and progression in patients with nephrotic syndrome, especially SRNS.

Role of the mechanisms for antibody repertoire diversification in monoclonal light chain deposition disorders: when a friend becomes foe

The adaptive immune system of jawed vertebrates generates a highly diverse repertoire of antibodies to meet the antigenic challenges of a constantly evolving biological ecosystem. Most of the diversity is generated by two mechanisms: V(D)J gene recombination and somatic hypermutation (SHM). SHM introduces changes in the variable domain of antibodies, mostly in the regions that form the paratope, yielding antibodies with higher antigen binding affinity. However, antigen recognition is only possible if the antibody folds into a stable functional conformation. Therefore, a key force determining the survival of B cell clones undergoing somatic hypermutation is the ability of the mutated heavy and light chains to efficiently fold and assemble into a functional antibody. The antibody is the structural context where the selection of the somatic mutations occurs, and where both the heavy and light chains benefit from protective mechanisms that counteract the potentially deleterious impact of the changes. However, in patients with monoclonal gammopathies, the proliferating plasma cell clone may overproduce the light chain, which is then secreted into the bloodstream. This places the light chain out of the protective context provided by the quaternary structure of the antibody, increasing the risk of misfolding and aggregation due to destabilizing somatic mutations. Light chain-derived (AL) amyloidosis, light chain deposition disease (LCDD), Fanconi syndrome, and myeloma (cast) nephropathy are a diverse group of diseases derived from the pathologic aggregation of light chains, in which somatic mutations are recognized to play a role. In this review, we address the mechanisms by which somatic mutations promote the misfolding and pathological aggregation of the light chains, with an emphasis on AL amyloidosis. We also analyze the contribution of the variable domain (V_L) gene segments and somatic mutations on light chain cytotoxicity, organ tropism, and structure of the AL fibrils. Finally, we analyze the most recent advances in the development of computational algorithms to predict the role of somatic mutations in the cardiotoxicity of amyloidogenic light chains and discuss the challenges and perspectives that this approach faces.

Understanding Mesangial Pathobiology in AL-Amyloidosis and Monoclonal Ig Light Chain Deposition Disease

Patients with plasma cell dyscrasias produce free abnormal monoclonal Ig light chains that circulate in the blood stream. Some of them, termed glomerulopathic light chains, interact with the mesangial cells and trigger, in a manner dependent of their structural and physicochemical properties, a sequence of pathological events that results in either light chain–derived (AL) amyloidosis (AL-Am) or light chain deposition disease (LCDD). The mesangial cells play a key role in the pathogenesis of both diseases. The interaction with the pathogenic light chain elicits specific cellular processes, which include apoptosis, phenotype transformation, and secretion of extracellular matrix components and metalloproteinases. Monoclonal light chains associated with AL-Am but not those producing LCDD are avidly endocytosed by mesangial cells and delivered to the mature lysosomal compartment where amyloid fibrils are formed. Light chains from patients with LCDD exert their pathogenic signaling effect at the cell surface of mesangial cells. These events are generic mesangial responses to a variety of adverse stimuli, and they are similar to those characterizing other more frequent glomerulopathies responsible for many cases of end-stage renal disease. The pathophysiologic events that have been elucidated allow to propose future therapeutic approaches aimed at preventing, stopping, ameliorating, or reversing the adverse effects resulting from the interactions between glomerulopathic light chains and mesangium.

Tubular Injury and Dendritic Cell Activation Are Integral Components of Light Chain-Associated Acute Tubulointerstitial Nephritis

CONTEXT.—

Light chain-associated acute tubulointerstitial nephritis (LC-ATIN) is a variant of light chain proximal tubulopathy (LCPT). It is characterized by interstitial inflammation with tubulitis and deposition of monoclonal light chains in the tubulointerstitium. LC-ATIN is a rather poorly recognized pattern of LCPT and not much is known about this entity.

OBJECTIVE.—

To determine the clinicopathologic features of patients with LC-ATIN and investigate the proximal tubular injury and mechanism of interstitial inflammation in LC-ATIN.

DESIGN.—

A total of 38 cases of LC-ATIN were identified from the archives of 5043 renal biopsy specimens. In all cases, routine light microscopic examination, immunofluorescence, and electron microscopic examination were performed. In selected cases, immunofluorescent staining of dendritic cells and immunohistochemical staining for 4 tubular injury markers-KIM-1, p53, bcl-2, and Ki-67-were performed.

RESULTS.—

A characteristic finding in LC-ATIN cases was immunofluorescence staining of monoclonal light chains along tubular basement membranes in linear fashion and inside proximal tubular cells with a granular pattern. No monoclonal light chains were present in glomerular or vascular compartments confirmed with immunofluorescence, electron microscopy, and ultrastructural gold labeling. Ten of 15 LC-ATIN cases (67%) were concurrently positive for the 4 tubular injury markers. Dendritic cells were identified within the tubulointerstitium in the renal biopsy specimens, interacting with surrounding tubules with light-chain deposits and inflammatory cells.

CONCLUSIONS.—

Significant proximal tubular injury occurs associated with LC-ATIN, and the monoclonal light chains accumulated in proximal tubular cells contribute to the injury. Dendritic cells are involved in the pathogenesis of interstitial inflammation in LC-ATIN.

The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance

Multiple myeloma (MM) is one of the most important clonal malignant plasma cell disorders and renal involvement is associated with poor prognosis. Although there are several reasons for renal impairment in MM, the main cause is the toxic effects of monoclonal proteins. Although cast nephropathy is the best known and unchallenged diagnosis for hematologists and pathologists, the renal effects of monoclonal gammopathy can be various. Monoclonal gammopathy of renal significance was proposed by the International Kidney and Monoclonal Gammopathy Research Group for renal lesions in monoclonal gammopathy in recent years. Renal lesions in monoclonal gammopathy can be grouped as follows: light chain (cast) nephropathy, acute tubular injury/necrosis, tubulointerstitial nephritis, amyloidosis, monoclonal Ig deposition diseases, immunotactoid glomerulopathy, type I cryoglobulinemia, proliferative glomerulonephritis with monoclonal IgG deposits, C3 glomerulopathy with monoclonal gammopathy, and crystal-storing histiocytosis, considering the previous and new terminology. In this study, renal involvement of monoclonal gammopathies, in terms of previous and new terminology, was reviewed.

Amyloid Proximal Tubulopathy and Amyloid Casts: An Unusual Finding in Multiple Myeloma

Patients with multiple myeloma (MM) often develop renal manifestations. The majority of cases present as cast nephropathy, amyloid light-chain (AL) amyloidosis, and monoclonal immunoglobulin deposition disease. AL amyloidosis usually involves the glomeruli, blood vessels, and interstitium. It is extremely uncommon to find isolated intratubular deposition of AL amyloid. Our patient presented with rapid worsening of renal function due to isolated intratubular deposition of AL amyloid, where the biopsy revealed amyloid proximal tubulopathy and amyloid cast nephropathy. Our case provides new insights into the complicated pathophysiology of the abnormal light chains in MM. This case is, to our knowledge, the second case of amyloid proximal tubulopathy reported in literature.

Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis

CONTEXT

Lesions associated with monoclonal light and heavy chains display a variety of glomerular, tubular interstitial, and vascular manifestations. While some of the entities are well recognized, including light and heavy chain deposition diseases, AL (light chain) and AH (heavy chain) amyloidosis, and light chain ("myeloma") cast nephropathy, other lesions centered on proximal tubules are much less accurately identified, properly diagnosed, and adequately understood in terms of pathogenesis and molecular mechanisms involved. These proximal tubule-centered lesions are typically associated with monoclonal light chains and have not been reported in patients with circulating monoclonal heavy chains.

OBJECTIVE

To determine the incidence of proximal tubulopathies in a series of patients with monoclonal light chain-related renal lesions and characterize them with an emphasis on clinical correlations and elucidation of molecular mechanisms involved in their pathogenesis.

DESIGN

A study of 5410 renal biopsies with careful evaluation of light microscopic, immunofluorescence, and electron microscopic findings was conducted to identify these monoclonal light/heavy chain-related lesions. In selected cases, ultrastructural immunolabeling was performed to better illustrate and understand molecular mechanisms involved or to resolve specific diagnostic difficulties.

RESULTS

In all, 2.5% of the biopsies were diagnosed as demonstrating renal pathology associated with monoclonal light or heavy chains. Of these, approximately 46% were classified as proximal tubule-centered lesions, also referred to as monoclonal light chain-associated proximal tubulopathies. These proximal tubulopathies were divided into 4 groups defined by characteristic immunomorphologic manifestations associated with specific clinical settings.

CONCLUSIONS

These are important lesions whose recognition in the different clinical settings is extremely important for patients' clinical management, therapeutic purposes, and prognosis. These entities have been segregated into 4 distinct variants, conceptualized morphologically and clinically. Specific mechanisms involved in their pathogenesis are proposed.

Role of translational research advancing the understanding of the pathogenesis of light chain-mediated glomerulopathies

Glomerulopathic light chains engage in pathological interactions with mesangial cells resulting in alterations in glomerular homeostasis. The crucial pathological events are centered in the mesangium and, therefore, research dealing with pathogenesis of these disorders is focused on this glomerular compartment. Particular physicochemical characteristics of these light chains are responsible for their ability to alter mesangial milieu leading to glomerular damage. An in vitro model has been used to dissect the processes involved. This model has been instrumental in providing a solid platform from which to observe in a dynamic fashion how mesangial cells handle pathogenic light chains and the sequential steps that are involved in the progressive glomerular damage. Key steps amenable to possible modulation have been defined and should provide a solid platform to design and test therapeutic interventions. In the past significant difficulties have been encountered in the development of animal models of light chain-induced glomerular damage. However, in the last few years a new generation of animal models has emerged to address whether what has been documented in vitro retains significance in vivo. Preliminary observations appear to substantiate this.

Ultrastructure of tubular casts

Tubular casts are found in a variety of conditions. Ultrastructural evaluation of casts has not been critically and systematically performed to define its usefulness. A total of 157 renal biopsies routinely processed for light microscopy (LM), immunofluorescence (IF), and electron microscopy (EM) were subjected to blind ultrastructural evaluation. The majority of the casts were in the distal nephron, and most of them (41.4%) were hyaline (HC). One-third (35%) of the cases showed admixed HC and granular casts (GC), and 25 cases (16%) had exclusively GC. In 7% of the cases, the morphology of the casts was distinctive enough to indicate specific composition. Four cases with red blood cell casts (5.6%) were associated with necrotizing glomerulopathy and IgA nephropathy. Four cases of myoglobulin casts were identified. Two cases with crystalized light-chain casts (1.3%) were associated with an underlying plasma cell dyscrasia. One case of acute pyelonephritis demonstrated polymorphonuclear cells casts (0.64%). A case of aminoglycoside toxicity revealed casts with myeloid bodies. Ultrastructural evaluation of casts may provide useful information that may be critical to establish or suggest a specific diagnosis.

Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory

One of the most prominent features of plasma cell dyscrasias is the frequent occurrence of renal dysfunction. Renal insufficiency is a common finding with elevated serum creatinine in more than 50% of patients with multiple myeloma at the time of diagnosis. Renal failure is the second most common cause of death in myeloma surpassed only by infections. The reasons for renal failure are multifactorial and early accurate diagnosis of the renal alterations may significantly impact morbidity and survival. Renal failure may result from selective glomerular, tubular interstitial, or vascular pathology or from a combination of pathologic events. The disorders associated with plasma cell dyscrasias include those characterized by monoclonal light chain deposition, encompassing AL-amyloidosis, in addition to the less well-characterized entities, such as heavy chain deposition disease and heavy chain amyloidosis. Therefore, it is more accurate to refer to them as monoclonal immunoglobulin deposition diseases. Staining of renal biopsy specimens for kappa and lambda light chains using immunofluorescence techniques and more sophisticated advanced diagnostic techniques such as immunoelectron microscopy permit detailed characterization of the various renal pathologic manifestations. Renal biopsies can identify monoclonal immunoglobulin deposition, and nephrologists have an opportunity to detect an underlying plasma cell dyscrasia early in its clinical course before overt hematologic alterations become manifest and irreversible renal damage has occurred. The overall spectrum of clinical and pathologic manifestations of monoclonal immunoglobulin deposition renal diseases has expanded considerably in recent years. Recent developments in the research arena promise new therapeutic interventions aimed at avoiding or ameliorating renal damage and even promoting reversal of some of the pathologic alterations. Currently, the 5-year survival rate in myeloma is 29% in white patients and 30% in African-American patients, a rather modest improvement from 24% in the 1970s. Bone marrow ablation followed by transplantation is available as an alternative mode of therapy that may be extraordinarily helpful in a subset of patients with early myeloma.

Renal lesions in rhabdomyolysis caused by Pseudechis australis snake myotoxin

The renal lesions at various time intervals after i.m. injection of Pseudechis australis myotoxin (PA myotoxin) causing myoglobinuria in mice was studied. Biochemical assay of serum creatine phosphokinase (CK) and lactate dehydrogenase (LDH) showed marked elevations [7166 +/- 2064 IU and 1626 +/- 211 Berger-Broida U/ml (B-B U/ml)] six hours after injection, indicative of rhabdomyolysis. Serum creatinine (1.6 +/- 0.39) and urea (147 +/- 40) showed significant rise by 48 hours indicative of acute renal failure (ARF). Immunodiffusion showed the presence of myoglobin in the urine (myoglobinuria) of experimental animals. Light microscopic (LM) and scanning electron microscopic (SEM) studies of the urinary sediments from experimental mice revealed granular casts of varying size and shape. LM of kidney showed casts from one hour and tubulopathy with degenerated tubular epithelial cell from 12 hours onwards. Focal glomerular changes, such as dilated Bowman's space with poorly stained substance and reduction in number of glomerular tufts were observed. Immunofluorescence microscopy for myoglobin showed fluorescence of the casts in the tubules. Transmission electron microscopy (TEM) showed electron dense casts occupying the entire lumen of the distal convoluted tubules (DCT). The proximal convoluted tubules (PCT) showed features of proximal tubular necrosis (PTN). There was reduction in the basal infolding with activation of lysosomal system in the PCT. The glomeruli showed changes in the visceral epithelium that included intracellular edema, vesiculation and occasional fusion of the podocytes. Numerous granular materials were observed in the Bowman's space as well as in the lumen of the capillaries from 1 to 24 hours. Electron dense deposits of the glomerular basement membrane (GBM) capillaries were observed from 1 to 24 hours. SEM study revealed loss of microvilli of the PCT and some tubular lumen were filled with cast like material. Some glomeruli displayed a relatively flattened podocytes with thickened major foot processes. Regeneration of the tubules were seen from three weeks onwards.

Presence of cerium-cytochemical reactions of glomerular phosphatases of normal gerbil Meriones crassus: an ultrastructural localization study

Phosphatase cytochemical activity in the normal glomerulus of the desert gerbil Meriones crassus was demonstrated using cerium ions as capturing agents. Three major enzymes have been recognized: sodium-potassium adenosine triphosphatase (Na(+)-K(+)-ATPase), alkaline phosphatase (ALPase) and acid phosphatase (ACPase). However, cytochemical staining for these markers to map their localizations and distributions reveal a high positivity of Na(+)-K(+)-ATPase. This appeared as uniform dense precipitates surrounding the glomerular basement membrane (GBM) and the plasma membranes of the epithelial and endothelial cells of the glomerular layers. Negligible ALKase reaction product being over the glomerular epithelia including the GBM. In contrast, the cytochemical profiles of ACPase was unusual, with dense reaction products extensively covering the endoplasmic reticulum at the region of Golgi apparatus products lysosomes (GERL) complex, including its cisternal and tubular elements and the lysosomal-vacuolar apparatus of the glomerular epithelial cells. All other subcellular organelles showed no activity. For Na(+)-K(+)-ATPase, the reaction product was successive when acetate buffer (as decalcifying agent, pH 5.0) was used. This reaction was still seen when a medium containing levamisole was used. Cytochemical controls for all enzymes were incubated in substrate-free media including those using levamisole as an inhibitor of ALPase. The data presented, which is reported for the first time, is not an attempt to determine the contribution of the selected phosphatases in the glomerular physiology and pathology. Such findings may, nevertheless, have functional implications in the fact that these markers may be involved in the ultrafiltration and other metabolic activities of the glomerulus at the molecular and/or cellular level. In addition to earlier morphological and recent histochemical work, the present study updates and recognizes information to be used as a baseline to which the gerbil model can now be employed to investigate the behavioural adaptations of the desert rodents.